Skip to main content
Top of the Page
The Society

About SOHO

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders. Since that time, nearly 7,000 members from 110 countries have joined the society from around the globe.

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information. Organized by its founders and world class committees, SOHO is the only international society specific to this field.

Society Structure

SOHO is led by a Board of Directors with eight voting members. In addition, an outstanding group of clinician-scientists have been assembled to serve on the Steering Committee to provide guidance and direction in the continued development of SOHO.

Two additional committees, Scientific and Education, are responsible for abstract review and the scientific program of the annual meetings, respectively. A third committee, Publication, is responsible for identifying opportunities for publishing work derived from the Society's activities. In addition, members of the Publication Committee manage the publication of papers for the society's featured article series, "SOHO State of the Art and Next Questions." Members of these groups are listed on the 'Committees' webpage.

Annual Meeting

The SOHO annual meeting has no parallel general sessions so that delegates may attend all sessions in sequential order. In addition, presentations are limited to the ‘latest advances’ allowing all topics to be covered in only 3.5 days. Last year, nearly 2,500 hematologic oncology experts gathered from around the world to share the latest clinical research impacting patient treatment at the hybrid 10th Annual Meeting of the Society of Hematologic Oncology. 

The eleventh annual meeting of the society, SOHO 2023, will be held as a hybrid event (in-person AND virtual) on September 6-9, 2023. Advances in leukemia, lymphoma, myeloma, myeloproliferative neoplasms, myelodysplastic syndromes and related malignancies will be highlighted during the official educational program. For more information and to register, visit

Official Journal

Clinical Lymphoma, Myeloma & Leukemia,” a peer-reviewed journal published by Elsevier, is the official journal of SOHO. It is available online free-of-charge to SOHO members and at a discounted rate in printed form (see journal).

News Publication

Blood Cancers Today,” is an official publication of the Society of Hematologic Oncology. BCT is a news-format publication that provides hematologists and oncologists with news, education, and information relevant to their patients and practices, with insight from experts in the field. As the online home of the publication, is updated daily, with the most current information from around the specialty and multimedia content, including exclusive interviews with presenters at major medical meetings. It is available online free-of-charge to the public and in print form free-of-charge to SOHO members (see BCT).


Become a Member



Study Suggests Link Between Aging, Low-Hypodiploid ALL

Posted on 9/21/2023
The proportion of low-hypodiploid ALL within Ph-negative B-cell ALL “dramatically increased with age.”

Can Novel Targeted Therapies Improve Outcomes for CRLF2-Rearranged B-ALL?

Posted on 9/21/2023
The median OS for the patients receiving targeted therapy was 11.8 months, while it was 5.8 months for the patients receiving conventional chemotherapy.

Researchers Uncover Mechanisms of BH3 Mimetic Resistance in T-cell ALL

Posted on 9/21/2023
Investigators studied mechanisms of resistance to BH3 mimetics to “develop rational combination strategies" for the treatment of T-cell ALL

Luspatercept Improved Anemia, Transfusion Burden in Myelofibrosis

Posted on 9/19/2023
The open-label ACE-536-MF-001 study evaluated luspatercept in cohorts of patients grouped by transfusion-dependance and ruxolitinib treatment status.

First-Line Selinexor, Ruxolitinib Shows Ongoing Promise for Myelofibrosis

Posted on 9/19/2023
Updated data from the phase I XPORT-MF-034 trial of selinexor plus ruxolitinib showed rapid, deep, and sustained spleen responses in patients with myelofibrosis.

SOHO DocMatter Community

A Global Hematologic Oncology Medical Community

SOHO has partnered with DocMatter, a global medical community platform, to offer a new benefit for SOHO members. This partnership, which joins two organizations committed to improving patient care and outcomes, creates a community for high-quality, clinical discussions among SOHO members. This SOHO-exclusive community will also allow for more open, in-depth discussions between members; from questions on cases to best practices. With this exclusive platform, SOHO members can connect with their peers easier than ever before.

With the SOHO-DocMatter Community, you can expect:

  • A secure, collaborative medical community so you can freely have open, in-depth discussions with your peers.
  • A DocMatter Clinician Advocate to provide technical support as well as personalize your notifications, settings and overall experience of the community based on your specific clinical interests.
  • Not a member? Join SOHO now to start utilizing the SOHO-DocMatter community and other SOHO-exclusive member benefits!

If you are logged in as a SOHO member, you may go directly to the SOHO-DocMatter Community.

SOHO Advocacy

The Society of Hematologic Oncology advocates our mission by uniting members around the world to discuss and unify the most advanced management and treatment approaches for patients with hematologic malignancies.

We initiate and manage programs with practices, cancer centers and countries, presenting the latest data and sharing new ways to treat and cure diseases within this complex group of malignancies.

Back to Top